Opigolix, also known as ASP1707, is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which was under development by Astellas Pharma for the treatment of endometriosis and rheumatoid arthritis. It was also under investigation for the treatment of prostate cancer. It reached phase II clinical trials for both endometriosis and rheumatoid arthritis prior to the discontinuation of its development in April 2018.
MedKoo Cat#: 561858
Name: Opigolix
CAS#: 912587-25-8
Chemical Formula: C25H19F3N4O5S
Exact Mass: 544.1028
Molecular Weight: 544.50
Elemental Analysis: C, 55.15; H, 3.52; F, 10.47; N, 10.29; O, 14.69; S, 5.89
The following data is based on the product molecular weight 544.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
